



14th Annual American Cancer Society Cancer Action Network Research & Health Equity Forum

Speaker Bios (in order of appearance)



Erin Miller

Erin Miller is Director of Business Development & Associate at SmithGroup. She is responsible for setting and driving the growth strategy for SmithGroup's integrated architecture and engineering design work in the New England region, across healthcare, life science, higher education and corporate workplace commercial markets.



Mark A. Goldberg, MD

Mark A. Goldberg, MD, is a medical oncologist and hematologist and a biotechnology executive. Dr. Goldberg is also a longtime American Cancer Society and American Cancer Society Cancer Action Network volunteer. Dr. Goldberg was a member of the American Cancer Society New England Division Board from 2010-2017. He has been a member of the national Board of Directors of the American Cancer Society since 2019. Additionally, he currently serves on the boards of directors of ImmunoGen, Idera Pharmaceuticals, GlycoMimetics, Blueprint Medicines, Walden Biosciences, and Avacta Group. He is an associate professor of Medicine (part-time) at Harvard Medical School. He received his AB from Harvard College (magna cum laude) and his MD (cum laude) from Harvard Medical School (Harvard MIT Program in Health Sciences and Technology).



William G. Kaelin, Jr., M.D.

William Kaelin is the Sidney Farber Professor of Medicine, in the Department of Medicine at the Dana-Farber Cancer Institute and the Brigham and Women's Hospital, Harvard Medical School. A Nobel laureate, Dr. Kaelin received the 2019 Nobel Prize in Physiology or Medicine. He is a member of the American Society of Clinical Investigation, the American College of Physicians, the National Academy of Sciences, the American Academy of Arts & Sciences and the National Academy of Medicine. He recently served on the NCI Board of Scientific Advisors, the AACR Board of Trustees, and the IOM National Cancer Policy Board. Dr. Kaelin obtained undergraduate and M.D. degrees from Duke University and completed his internal medicine training at the Johns Hopkins Hospital, where he served as chief medical resident. He was a clinical fellow in medical oncology at the Dana-Farber Cancer Institute and a postdoctoral fellow in the laboratory of David Livingston, during which time he was a McDonnell Scholar.



Shalini Vallabhan, PhD

Shalini Vallabhan is a strategic director for the American Cancer Society Cancer Action Network and is leading alliance development in the Northeastern U.S. from DC to Maine. After completing her PhD with a focus on health policy, she served as a legislative aide in the US Congress. Following that, Shalini directed the policy research team for the American Cancer Society and went on to work in Asia to launch in-country public health capacity building programs in India, China, and Southeast Asia for community-based organizations and governments. Shalini holds a PhD in political science from Texas A&M University.



Rebecca Stevenson

Rebecca Stevenson (Becky) is a Managing Director on the Biopharma Investment Banking team within the Healthcare Corporate & Investment Banking Group at Wells Fargo where she advises, and executes on behalf of, biopharma companies' long-term strategic financing, M&A, partnership and overall business development strategies. Becky also runs the Biopharma teams Venture Capital & Institutional investor coverage effort. Becky graduated from Tulane University's A.B. Freeman School of Business with a BSM in Finance and BA in Spanish. Becky is a Member of the Board of Directors for the American Cancer Society's New England Chapter and an avid volunteer for causes focused on improving the environment, education, and food insecurity.



Melaina Boyce

Melaina Boyce is Head of In-Country Study Operations for EMD Serono, responsible for the delivery of the development clinical studies across therapeutic areas of oncology, neurology and immunology in the US, Canada and Latin America. She has over 18 years of experience in clinical operations and is passionate about driving innovation to reduce patient and site burden. Driving in her organization process and infrastructure for patient engagement, Melaina is also leading the Diversity and Inclusion Strategy for Clinical Trials within EMD with a mission to integrate strategies that re-enforce an inclusive mindset in the development framework. Melaina has strong international and leadership experience having lead teams and projects in North America, Europe and Asia. Melaina completed her Bachelor of Science in Biology from the University of Western Ontario and a post graduate program in Clinical Research from Humber College.



Reid Huber, PhD

Reid Huber joined Third Rock Ventures in 2018 as a partner, bringing more than 20 years of leadership and experience to the role. He focuses on the formation, development and strategy of Third Rock's portfolio companies. Reid joined the firm from Incyte, where he was a member of the founding scientific team and most recently served as executive vice president and chief scientific officer. At Incyte, he held roles of increasing responsibility across multiple therapeutic areas in both drug discovery and clinical development. In 2011, he assumed responsibility for the company's research activities as Senior Vice President, Discovery Biology. Before joining Incyte, Reid held scientific research positions at DuPont and Bristol-Myers Squibb from 1998 to 2002. He received his Ph.D. in molecular genetics from the Washington University School of Medicine and held predoctoral and postdoctoral fellowships at the National Institutes of Health. Reid is a board director at Tango Therapeutics, MOMA Therapeutics and Asher Bio.



Thea James, MD

Thea James, MD, is Vice President of Mission and Associate Chief Medical Officer at Boston Medical Center (BMC). She is the Director of BMC Violence Intervention Advocacy Program and Associate Professor of Emergency Medicine at Boston University School of Medicine. Dr. James has primary responsibility for coordinating and maximizing BMC's relationships and strategic alliances with local, state, and national organizations to foster innovative and effective models of care that are essential for patients and communities to thrive. Dr. James served on the Massachusetts Board of Registration in Medicine 2009-2012 as chair of the Licensing Committee. As the Supervising Medical Officer on the Boston Disaster Medical Assistance Team under the Department of Health and Human Services, Dr. James has deployed to New York City post 9/11; New Orleans after Hurricane Katrina in 2005; Bam, Iran after the 2003 earthquake; and Port-Au-Prince, Haiti after the 2010 earthquake. A graduate of Georgetown University School of Medicine, Dr. James trained in Emergency Medicine at Boston City Hospital, where she was a chief resident.



Beverly Moy, MD, MPH

Dr. Moy is the Director of Cancer Equity, Clinical Director of the Breast Oncology Program, and a medical oncologist at the Massachusetts General Hospital. She is an Associate Professor of Medicine at Harvard Medical School. She received her undergraduate education at the Johns Hopkins University and her medical degree at the Albert Einstein College of Medicine. Dr. Moy completed her internal medicine residency training at Brigham and Women's Hospital and her hematology-oncology fellowship at Beth Israel Deaconess Medical Center. She received a Master's degree in Public Health at the Harvard School of Public Health. Dr. Moy's specific research interests include breast cancer clinical trials and racial and ethnic disparities in cancer care.

Kate Weissman



Kate Weissman is a five-year Stage 2B cervical cancer survivor. She has been an ACS CAN Lead Ambassador for Massachusetts Congressional District 7 since 2018. Kate also volunteers with Cervivor, an organization dedicated to educating people about cervical cancer, HPV, and HPV vaccinations, and the Alliance for Proton Therapy Access. She lives in Charlestown with her husband Matt, their baby daughter Louella, and dog Giada. She is the Vice President of Integrated Project Management at a Public Relations agency, and an avid food enthusiast.